COVID-19大流行对葡萄膜炎患者诊疗的影响
该研究为多中心横断面调查,通过国际葡萄膜炎学会邮件列表向全球葡萄膜炎专家发放网络问卷,评估疫情对患者诊疗、免疫调节治疗(IMT)使用及COVID-19疫苗接种考量的影响。187名来自六大洲的专家参与,多数报告临床管理中断,多数基于临床表现启动和继续IMT,几乎全体推荐接种COVID-19疫苗。
要点
- 多数专家报告临床管理中断,包括诊所关闭或容量减少、患者因恐惧感染错过面诊及实验室检测困难。
- 多数参与者基于临床表现启动(66.8%)和继续(93.3%)IMT,未改变免疫抑制剂使用。
- 73.0%的应答者在COVID-19感染时推荐暂停全部或部分IMT,几乎全体专家推荐接种COVID-19疫苗。
核心结论
- 自大流行开始以来,葡萄膜炎患者诊疗已发生显著变化,随着IMT和疫苗接种新数据的出现,建议将继续演变。
研究设计与样本
- 多中心横断面调查,通过国际葡萄膜炎学会邮件列表向全球执业的葡萄膜炎专家发放网络问卷,评估患者诊疗修改、IMT使用及COVID-19疫苗接种考量。
主要发现
- 187名来自六大洲的葡萄膜炎专家参与调查,多数专家指出患者临床管理中断,包括诊所关闭或容量减少、患者因恐惧感染错过面诊及实验室检测困难。
- 多数参与者基于临床表现启动(66.8%)和继续(93.3%)IMT,未修改免疫抑制剂使用。
- 在报告暴露于COVID-19感染的情况下,多数参与者(65.3%)建议不改变IMT;然而73.0%的应答者推荐在COVID-19感染时暂停全部或部分IMT。
- 几乎全体专家普遍推荐COVID-19疫苗,52%表示会告知患者疫苗在免疫抑制患者中免疫原性和有效性降低。
关键数值与推荐
- 启动IMT的参与者比例为66.8%,继续IMT的参与者比例为93.3%,均基于临床表现。
- 报告暴露于COVID-19感染时,65.3%的参与者建议不改变IMT。
- COVID-19感染时,73.0%的应答者推荐暂停全部或部分IMT。
- 52%的专家表示会告知患者疫苗在免疫抑制患者中免疫原性和有效性降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has significantly changed practice of medicine and patient care worldwide. The impact of the pandemic on patients with uveitis is unknown. We developed the COVID-19 Practice Patterns Study Group to evaluate the effect of the pandemic on uveitis patient care. METHODS: This is a multicentre, cross-sectional survey of uveitis specialists practising worldwide. A web-based survey was distributed through the mailing lists of international uveitis societies to assess modifications in patient care, and use of immunomodulatory therapies (IMTs),aswell as considerations regarding COVID-19 vaccination. RESULTS: A diverse group consisting of 187 uveitis specialists from six continents participated in this survey. Most of these experts noted a disruption in clinical management of patients, including clinic closures or decrease in volume, patients missing in-person visits due to the fear of infection and difficulties obtaining laboratory testing. Most participants initiated (66.8%) and continued (93.3%) IMTs based on clinical presentation and did not modify their use of immunosuppressives. In cases of reported exposure to COVID-19 infection, most participants (65.3%) recommended no change in IMTs. However, 73.0% of the respondents did recommend holding all or select IMTs in case of COVID-19 infection. COVID-19 vaccine was recommended universally by almost all the specialists and 52% stated that they would counsel patients regarding the decreased immunogenicity and effectiveness of the vaccine in immunocompromised patients. CONCLUSIONS: Uveitis patient care has changed significantly since the beginning of the pandemic. The recommendations will continue to evolve as new data on IMTs and vaccination become available.
引用
- Vu AF, Kodati S, Lin P, et al. Impact of the COVID-19 pandemic on uveitis patient care. Br J Ophthalmol. 2022. PMID: 35074784. doi:10.1136/bjophthalmol-2021-320368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。